The positive Phase 2a data and clean safety profile represent a significant de-risking of bempikibart, likely driving a strong near-term rally. Monitor the upcoming medical meeting presentations and initiation of the registrational program in H1 2027. The debt payoff removes balance sheet overhang, but the company will likely need additional financing to fund the registrational trial.
Drug in focus
QTTB drug pipeline →bempikibart
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.
- Next catalyst
- None dated
What to watchThe July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027, but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $21.38entry
- T+1 · 4mo ago −13.66%α −14.01% · $18.46
- T+5 · 4mo ago −29.61%α −28.82% · $15.05
- T+20 · 3mo ago −26.71%α −29.89% · $15.67
- T+60 · 6w ago −62.07%α −66.06% · $8.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Q32 Bio reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata, showing a 35.3% mean reduction in SALT score and 40% SALT-20 response in the mITT population with a favorable safety profile. The company also disclosed it paid off the remaining ~$6.8M loan from Silicon Valley Bank, eliminating debt. The data supports advancement to a registration-directed program in H1 2027, a significant milestone for this clinical-stage biotech.
Key Facts
- Mean SALT score reduction of 35.3% in mITT population at Week 36
- 40.0% (10/25) of mITT patients achieved SALT-20 (80% scalp hair coverage) at Week 36
- 30.3% (10/33) of ITT patients achieved SALT-20
- 44.0% (11/25) mITT achieved both SALT30 and SALT50 responses
- No serious adverse events or Grade 3+ treatment-related adverse events observed
- Injection site reactions were the most common TEAE (36.3%) but were mild and self-resolving
- Company intends to advance bempikibart into a registration-directed program in first half of 2027
- Paid off remaining ~$6.8M loan from Silicon Valley Bank on June 24, 2026, terminating the Loan Agreement
Financial Impact
No revenue for this clinical-stage company. Positive Phase 2a data de-risks lead asset (bempikibart) in alopecia areata, a ~700,000-patient US market. Debt elimination (~$6.8M) improves balance sheet.
Risk Factors
- Open-label, single-arm design with small sample (n=33) limits data robustness
- Durability data beyond Week 36 off-drug follow-up is still immature
- Registrational trial execution and potential regulatory hurdles ahead
- Competition from JAK inhibitors and other emerging therapies for alopecia areata
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-301464 |
| Document: d142528dex991.htm | 0001193125-26-301464 |
| Document: 0001193125-26-301464-index-headers.html | 0001193125-26-301464 |
| Document: 0001193125-26-301464-index.html | 0001193125-26-301464 |
| Document: 0001193125-26-301464.txt | 0001193125-26-301464 |
Track record
23 reports on QTTB
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers